Graft-versus-host Disease
📧 Sign up to get email alerts when something new happens for Graft-versus-host Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-11-19Clinical Trial Update: Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study
The PQRST study aims to predict the quality of response to treatments in patients with chronic graft-versus-host disease and is currently re…
-
CLINICAL_TRIALS other · 2025-11-18Clinical Trial Update: Managed Access Programs for INC424, Ruxolitinib
Novartis-sponsored update on managed access programs for INC424 (ruxolitinib), outlining eligible indications including primary myelofibrosi…
-
CLINICAL_TRIALS trial_result · 2025-11-18Clinical Trial Update: Effects of Omega-3 Fatty Acids on Acute Graft-versus-Host Disease After Allogeneic Stem Cell Transplantation. [Phase 1, Phase 2]
A clinical trial update shows omega-3 fatty acids are being studied for their effects on acute graft-versus-host disease following allogenei…
-
CLINICAL_TRIALS trial_result · 2025-11-18Clinical Trial Update: Psychosocial Mobile App for Chronic Graft-Versus-Host Disease [NA]
This clinical trial update notes a psychosocial mobile app being studied for chronic graft-versus-host disease; the study is currently activ…
-
CLINICAL_TRIALS other · 2025-11-13Clinical Trial Update: Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation [Phase 1]
The document reports that a Phase 1 study evaluating allogeneic CD6-CAR T regulatory cells for chronic graft-versus-host disease after allog…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2025-11-10EMA Authorised: Jakavi (ruxolitinib phosphate) — Novartis Europharm Limited
Jakavi (ruxolitinib phosphate) has been authorised in the EU with indications for polycythemia vera and graft-versus-host disease. The decis…
-
CLINICAL_TRIALS withdrawal · 2025-11-10Clinical Trial Update: Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias [Phase 2]
An extension study of fostamatinib (Syk inhibitor) for posttransplant immune-mediated cytopenias has been withdrawn, including autoimmune he…
-
CLINICAL_TRIALS trial_result · 2025-11-05Clinical Trial Update: Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease [Phase 2]
This Phase 2 trial update evaluates acalabrutinib for chronic graft-versus-host disease. The study is active but not currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-10-30Clinical Trial Update: Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD Participants [Phase 2]
Phase 2 trial update evaluating Prochymal for salvage therapy in treatment-refractory acute graft-versus-host disease, reporting safety and …
-
CLINICAL_TRIALS trial_result · 2025-10-30Clinical Trial Update: Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. [Phase 4]
This Phase 4 trial update describes extending ibrutinib treatment for patients who continue to benefit from the therapy.
-
CLINICAL_TRIALS research · 2025-10-23Clinical Trial Update: The Prevalence of Hypoesthesia Related Keratitis in Ocular Graft Vs. Host Disease (GVHD) Patients
Indiana University is conducting a study to determine how common hypoesthesia-related keratitis is in patients with ocular graft-versus-host…
-
FDA approval · 2025-10-21FDA Approved: IMBRUVICA — Supplemental Application (Pharmacyclics LLC)
FDA approved a supplemental application for IMBRUVICA (ibrutinib) submitted by Pharmacyclics LLC.
-
CLINICAL_TRIALS trial_result · 2025-10-21Clinical Trial Update: Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD) [Phase 1, Phase 2]
This update reports on a completed Phase 1/2 dose-finding and safety study of ibrutinib in pediatric patients with chronic graft-versus-host…
-
CLINICAL_TRIALS trial_result · 2025-10-20Clinical Trial Update: Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD) [Phase 2]
Phase 2 proof-of-concept trial of apraglutide in acute graft-versus-host disease was terminated; results have been posted.
-
CLINICAL_TRIALS research · 2025-10-20Clinical Trial Update: IS-free Treg HaploHCT [Phase 1]
A Phase 1 clinical trial at Dana-Farber Cancer Institute evaluating an IS-free regulatory T cell haploidentical hematopoietic cell transplan…
-
CLINICAL_TRIALS research · 2025-10-20Clinical Trial Update: Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients
A clinical trial evaluating Parametric Response Mapping as a way to detect chronic lung injury in hematopoietic cell transplant recipients; …
-
CLINICAL_TRIALS trial_result · 2025-10-14Clinical Trial Update: Treatment Use of the CliniMACS® CD34 TCR Alpha/Beta for Allogenic Transplant (Expanded Access Use)
Clinical trial update describing expanded access use of CliniMACS CD34 TCR Alpha/Beta for allogeneic transplantation.
-
CLINICAL_TRIALS trial_result · 2025-10-14Clinical Trial Update: A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease. [Phase 3]
Phase 3 trial update for belumosudil in combination with corticosteroids in newly diagnosed chronic graft-versus-host disease; the study is …
-
CLINICAL_TRIALS research · 2025-10-08Clinical Trial Update: Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant [Phase 2]
Phase 2 trial evaluating a two-step anti-thymocyte globulin (ATG) regimen to prevent acute graft-versus-host disease after myeloablative all…
-
CLINICAL_TRIALS research · 2025-10-08Clinical Trial Update: Expanded Access of Axatilimab to Treat a Single Patient With Chronic Graft Versus Host Disease (GVHD)
This document reports expanded access of axatilimab to treat a single patient with chronic graft-versus-host disease (GVHD). It provides sta…
-
CLINICAL_TRIALS research · 2025-10-07Clinical Trial Update: HCMV-miRNA Monitoring After Allogeneic Hematopoietic Stem Cell Transplantation Using PSTM-qPCR
A clinical trial update describing a study on monitoring HCMV using PSTM-qPCR after allogeneic hematopoietic stem cell transplantation; the …
-
CLINICAL_TRIALS trial_result · 2025-10-02Clinical Trial Update: Close Assessment and Testing for Chronic Graft Versus Host Disease, CATCH Study
Update on the CATCH study evaluating close assessment and testing for chronic graft-versus-host disease. The trial status is completed.
-
CLINICAL_TRIALS research · 2025-09-30Clinical Trial Update: Treatment of Refractory cGVHD by Donor-derived Treg Cell Injection Combined With Recombinant Human Interleukin-2 [EARLY_Phase 1]
This EARLY_PHASE1 clinical trial from Shanghai General Hospital evaluates a combination of donor-derived regulatory T cell injections and re…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: Study of Gecacitinib in the Treatment of Acute Graft-Versus-Host Disease After Failure of Ruxolitinib-containing Second-line Therapy [Phase 2]
Phase 2 clinical trial evaluating Gecacitinib for acute graft-versus-host disease after failure of ruxolitinib-containing second-line therap…
-
CLINICAL_TRIALS trial_result · 2025-09-26Clinical Trial Update: TDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD)) [Phase 1, Phase 2]
An update on the Phase 1/2 trial of TDI01 for chronic graft-versus-host disease, noting a recruitment suspension and current status as activ…